Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Leukemia, Myeloid, Acute 38Breast Neoplasms 38Lymphoma, Large B-Cell, Diffuse 36Multiple Myeloma 31Lymphoma, Non-Hodgkin 30Burkitt Lymphoma 29Lymphoma 28Myelodysplastic Syndromes 25Triple Negative Breast Neoplasms 23Recurrence 23Lymphoma, B-Cell 22Hematologic Neoplasms 22Lymphoma, Follicular 20Ovarian Neoplasms 15Melanoma 15Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Neoplasm Metastasis 13Hodgkin Disease 13Neoplasms 12Leukemia, Biphenotypic, Acute 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Pancreatic Neoplasms 10Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Carcinoma, Non-Small-Cell Lung 10Lymphoma, T-Cell, Peripheral 9

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Malignant Neoplasm × Cyclophosphamide × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡